CNPY3 and neoplasm: Intriguingly, targeting CNPY3 in human ER+PR+ and TNBC cells by CRISPR/Cas9 significantly decreased tumor growth, prolonged survival, and reduced metastasis in vitro and in vivo (Figure 4).